The pen lacks a linear plunger rod; instead, a spring pushes the cartridge piston. This enables lower injection force (≈6–10 N vs. 15–20 N for manual insulin pens), benefiting patients with reduced hand strength.
There are three distinct Ozempic pen packages available in the U.S. market: ozempic 1 mg pen
The (blue label) is a once-weekly maintenance injection primarily used to manage Type 2 diabetes and reduce the risk of major cardiovascular events. Each pen contains 4 mg of semaglutide in a 3 mL solution, designed to deliver exactly four weekly doses of 1 mg . Key Benefits and Uses The pen lacks a linear plunger rod; instead,
The Ozempic 1 mg pen (Novo Nordisk) is a prefilled, disposable injection device for once-weekly semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA). This paper dissects the pen’s mechanical design, dose accuracy, human factors engineering, and real-world adherence implications. Unlike multi-dose insulin pens, the Ozempic pen delivers fixed doses (0.25 mg, 0.5 mg, or 1.0 mg depending on the pen version) with a color-coded, spring-assisted mechanism. The 1 mg pen specifically contains 4 mg semaglutide in 3 mL solution (1.34 mg/mL), delivering four 1 mg doses plus a mandatory flow-check prime. We evaluate its engineering trade-offs: reliability of the dose counter, injection force variability, residual volume, and patient error patterns. There are three distinct Ozempic pen packages available
This report is for informational purposes only and does not constitute medical advice. Ozempic is a prescription medication with significant biological effects. Patients must consult a healthcare provider for diagnosis, treatment, and management of Type 2 Diabetes or weight-related conditions.